On December 27, 2016, Amphastar revealed that Armstrong Pharmaceuticals, Inc. ("Armstrong"), its wholly-owned subsidiary, was issued a complete response letter from the U.S. Food and Drug Administration ("FDA"), stating that Armstrong's New Drug Application for Primatene Mist, an epinephrine inhalation aerosol product, will not be approved in its present form. The FDA specified that Armstrong needs to change the product's label and packaging and it should conduct another Human Factor validation study to assess consumers' ability to use the product without the guidance of a doctor or pharmacist. Following this news, Amphastar stock dropped $1.86 per share, or 9.1%, to close at $18.57 on December 27, 2016.
If you are aware of any facts relating to this investigation, or purchased Amphastar shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/amph. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-amphastar-pharmaceuticals-inc-amph-300383746.html
SOURCE Bronstein, Gewirtz & Grossman, LLC